Dianthus Therapeutics, Inc. /DE/
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
DNTH$90.00+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information required under this item is incorporated herein by reference to the Proxy Statement, including under the heading“Executive Compensation.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.